TY - JOUR T1 - Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection JF - medRxiv DO - 10.1101/2021.05.07.21256823 SP - 2021.05.07.21256823 AU - Floriane Gallais AU - Pierre Gantner AU - Timothée Bruel AU - Aurelie Velay AU - Delphine Planas AU - Marie-Josée Wendling AU - Sophie Bayer AU - Morgane Solis AU - Elodie Laugel AU - Nathalie Reix AU - Anne Schneider AU - Ludovic Glady AU - Baptiste Panaget AU - Nicolas Collongues AU - Marialuisa Partisani AU - Jean-Marc Lessinger AU - Arnaud Fontanet AU - David Rey AU - Yves Hansmann AU - Laurence Kling-Pillitteri AU - Olivier Schwartz AU - Jérome De Sèze AU - Nicolas Meyer AU - Maria Gonzalez AU - Catherine Schmidt-Mutter AU - Samira Fafi-Kremer Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/17/2021.05.07.21256823.abstract N2 - Assessment of the kinetics of SARS-CoV-2 antibodies is essential in predicting protection against reinfection and durability of vaccine protection. Here, we longitudinally measured Spike (S) and Nucleocapsid (N)-specific antibodies in 1,309 healthcare workers (HCWs), including 916 COVID-19 negative HCWs and 393 convalescent COVID-19 for up to 422 days post-symptom. From month (M)1 to M7-9 post-infection, SARS-CoV-2 antibodies decreased moderately in convalescent HCWs in a biphasic model, with men showing a slower decay of anti-N (p=0.02), and a faster decay of anti-S (p=0.0008) than women. At M11-13, anti-N dramatically decreased (half-life: 283 days) while anti-S stabilized (half-life: 725 days) at a median of 2.39 log Arbitrary Units (AU)/mL (Interquartile Range (IQR): 2.10 -2.75). Overall, 69 SARS-CoV-2 infections developed in the COVID-19 negative group (incidence of 12.22 per 100 person-years) versus one in the COVID-19 positive group (incidence of 0.40 per 100 person-years), indicating a relative reduction in the incidence of SARS-CoV-2 reinfection of 96.7% (p<0.0001). Correlation with live-virus neutralization assay revealed that variants D614G and B.1.1.7, but not B.1.351, were sensitive to anti-S antibodies at 2.3 log AU/mL, while IgG ≥ 3 log AU/mL neutralized all three variants. After SARS-CoV-2 vaccination, anti-S levels reached at least 3 logs regardless of pre-vaccination IgG levels, type of vaccine, and number of doses. Our study demonstrates a long-term persistence of anti-S IgG antibodies that may protect against reinfection. By significantly increasing cross-neutralizing antibody titers, a single-dose vaccination strengthens protection against escape mutants.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov Identifier: NCT04441684Funding StatementThis work was supported by Strasbourg University Hospitals (SeroCoV-HUS; PRI 7782), the Agence Nationale de la Recherche (ANR-18-CE17-0028), Laboratoire d'Excellence TRANSPLANTEX (ANR-11-LABX-0070_TRANSPLANTEX), and Institut National de la Sante et de la Recherche Medicale (UMR_S 1109).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CPP Sud-Mediterranee 3, CHU de Nimes, Place du Professeur Robert Debre, 30029 Nimes Cedex 9 reference: 2020.04.15 bis_ 20.04.10.66856All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon request to the corresponding author ER -